Tiotropium, a long-acting muscarinic antagonist (LAMA), has bronchodilator properties by antagonizing muscarinic receptors in the airway smooth muscle. In Japan, the tiotropium Soft Mist™ Inhaler (Spiriva® Respimat®) was approved for severe persistent asthma in 2014 and gained approval for asthma with all severity levels in 2016. The UniTinA-asthma® clinical development program, which evaluated the efficacy and safety of tiotropium Soft Mist Inhaler, consisted of 18 clinical trials (phase II, 7 studies; phase III, 11 studies) with over 6000 patients. The phase III UniTinA-asthma® program covered all severity levels of asthma among a broad age range of patients containing children (ages 1-17 years) and adults. In this review, we describe characteristics of tiotropium and each result of phase III studies in UniTinA-asthma® to investigate the efficacy and safety of tiotropium for asthma.
|Number of pages||12|
|Publication status||Published - 2017|
- Long-acting muscarinic antagonist (LAMA)
ASJC Scopus subject areas